Statistics from Altmetric.com
The first-generation rotavirus vaccine RotaShield was withdrawn in 1999 because of a 1 in 10 000 risk of intussusception. The second-generation vaccines—RotaTeq, a pentavalent bovine-human reassortant vaccine, and Rotarix (RV1), a monovalent human vaccine—underwent extensive clinical trials with no apparent increased risk of intussusception. In 2006–2007, Brazil and Mexico introduced routine infant immunisation with RV1. Now, a study in both countries (Manish M Patel, and colleagues. New Engl J Med 2011;364:2283–92; …
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.